Eli Lilly And Co vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Eli Lilly And Co trades at $1,220.55 (market cap $1.08T), while iShares 10 20 Year Treasury Bond ETF trades at $96.58. The key difference: Eli Lilly And Co pays a 0.57% dividend while iShares 10 20 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals.
| LLY | TLH | |
|---|---|---|
Market Cap | $1.08T | — |
Sector | Health | Fixed Income |
52-Week High | $1.24K | $105.36 |
52-Week Low | $639.43 | $96.39 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
TLH trades at $96.62 with minimal daily movement (+0.24%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock faces resistance at $97 and support at $96. Recent dividend payments of $0.38, $0.36, and $0.41 in mid-2026 indicate ongoing shareholder returns despite the challenging technical backdrop.
The outlook remains cautious with bearish technical signals dominating. Key resistance at $97 must be breached for bullish momentum. Dividend consistency provides some stability, but the lack of fundamental data and weak technical structure suggests limited near-term upside potential for investors.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →